Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Christopher Goetz and Katie Kompoliti.
Christopher Goetz
Connection Strength
2.075
Katie Kompoliti
  1. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.210
  2. TikTok Tics: A Pandemic Within a Pandemic. Mov Disord Clin Pract. 2021 Nov; 8(8):1200-1205.
    View in: PubMed
    Score: 0.199
  3. Rating scales and quantitative assessment of tics. Adv Neurol. 2001; 85:31-42.
    View in: PubMed
    Score: 0.191
  4. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.190
  5. Therapeutic approaches. Adv Neurol. 2000; 82:217-21.
    View in: PubMed
    Score: 0.178
  6. Neuropharmacology in the elderly. Neurol Clin. 1998 Aug; 16(3):599-610.
    View in: PubMed
    Score: 0.161
  7. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov Disord. 1998 May; 13(3):477-80.
    View in: PubMed
    Score: 0.159
  8. Tourette syndrome. Clinical rating and quantitative assessment of tics. Neurol Clin. 1997 May; 15(2):239-54.
    View in: PubMed
    Score: 0.148
  9. Association between antipsychotics and body mass index when treating patients with tics. J Child Adolesc Psychopharmacol. 2010 Aug; 20(4):277-81.
    View in: PubMed
    Score: 0.093
  10. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.085
  11. Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
    View in: PubMed
    Score: 0.068
  12. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519.
    View in: PubMed
    Score: 0.050
  13. Estrogen supplementation in the posthypoxic myoclonus rat model. Clin Neuropharmacol. 2001 Jan-Feb; 24(1):58-61.
    View in: PubMed
    Score: 0.048
  14. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
    View in: PubMed
    Score: 0.045
  15. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
    View in: PubMed
    Score: 0.045
  16. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
    View in: PubMed
    Score: 0.045
  17. Movement disorders in Kuru. Mov Disord. 1999 Sep; 14(5):800-4.
    View in: PubMed
    Score: 0.043
  18. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998 Aug; 55(8):1099-102.
    View in: PubMed
    Score: 0.040
  19. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998 Jul; 55(7):957-61.
    View in: PubMed
    Score: 0.040
  20. Progressive cognitive decline with truncal/limb ataxia and ballistic movements. Mov Disord. 1997 Nov; 12(6):1075-84.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.